At a glance
What is it—and why does it matter?
Cagrilintide is listed as a peptide-based amylin receptor agonist (AMYRA). In adults with type 2 diabetes and BMI 27 or higher, once-weekly cagrilintide-semaglutide (2.4 mg each) for 68 weeks reduced body weight more than placebo. Compared with normal kidney function, AUC0-∞ ratios were 1.23 (0.91-1.66) mild, 1.18 (0.87-1.59) moderate, and 1.21 (0.87-1.68) severe impairment.
Sources for this introduction: [1] [2] [3]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
Simple guide
Cagrilintide, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
Cagrilintide is a lipidated, long-acting version of the peptide amylin.
Source for this finding
“Biologically it is a lipidated, long-acting analogue of the anorexigenic peptide amylin.”
IUPHAR ligand commentary
What the research looks like
Most published findings come from studies in people.
- 49 People 61%
- 12 Animals or lab 15%
- 19 Other or unclear 24%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
For assay sensitivity, placebo-arm participants received a single 400 mg oral moxifloxacin dose (positive control) and moxifloxacin placebo in a nested crossover.
Source for this finding
“To establish QT assay sensitivity, participants in the placebo arms received a single 400‐mg oral moxifloxacin dose as a positive control and moxifloxacin placebo in a nested cross‐over fashion.”
Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participantsAt week 40, cagrilintide-semaglutide reduced bodyweight more than placebo: treatment difference -12·4 percentage points (2·4 mg each) and -10·4 percentage points (1·0 mg each).
Source for this finding
“Cagrilintide-semaglutide was superior to placebo with respect to estimated mean relative change in bodyweight from baseline to week 40 for cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001) and cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001).”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.From baseline to week 40, bodyweight decreased more with cagrilintide-semaglutide (2·4 mg each) than placebo by -12·4 percentage points (95% CI -14·7 to -10·1; p<0·0001).
Source for this finding
“Cagrilintide-semaglutide was superior to placebo with respect to estimated mean relative change in bodyweight from baseline to week 40 for cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001) and cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001).”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Compared with placebo at 40 weeks, HbA1c was lower by -1·7 percentage points with cagrilintide-semaglutide (2·4 mg each) and by -1·3 percentage points with (1·0 mg each).
Source for this finding
“This corresponded to an estimated treatment difference of -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001) for cagrilintide-semaglutide (2·4 mg each) versus placebo and -1·3 percentage points (-1·8 to -0·9; p<0·0001) for cagrilintide-semaglutide (1·0 mg each) versus placebo.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.A systematic review and meta-analysis compared cagrilintide alone with semaglutide in people with obesity.
Source for this finding
“We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.”
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
In lean rats, eloralintide caused less conditioned taste avoidance than cagrilintide (p < 0.05).
Source for this finding
“Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05).”
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Acute cagrilintide changes gene expression in area postrema Calcr/Ramp3 neurons.
Source for this finding
“While acute cagrilintide treatment alters gene expression in area postrema Calcr/Ramp3 neurons, chemogenetic activation in rats fails to affect long-term food intake and body weight.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.Cagrilintide was tested for effects on mitochondria in C2C12 muscle cells under healthy and palmitic-acid conditions.
Source for this finding
“This study aimed to investigate the effects of semaglutide (GLP-1RA), tirzepatide (dual GLP-1/GIP agonist) and cagrilintide (amylin analogue) on mitochondrial function in C2C12 skeletal muscle myotubes under both healthy and lipotoxic (palmitic acid-treated) conditions.”
Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
Safety
No safety findings are published in this profile yet. Missing safety data does not mean it is safe.
What we don't know
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
A missing finding does not mean something is safe or effective.
See all 98 findings and sourcesEvery finding, grouped by topic, with its exact source passages
What is it?
A molecule, not a product name.
Identity
Cagrilintide is a lipidated, long-acting version of the peptide amylin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Biologically it is a lipidated, long-acting analogue of the anorexigenic peptide amylin.”
IUPHAR ligand commentary · General comments
Identity
Cagrilintide is a non-selective amylin receptor agonist.
1 cited source · 1 linked study ID
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05).”
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. · RESULTS
Identity
Cagrilintide is a peptide (Ligand ID: 13768).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Name: cagrilintide Ligand ID: 13768 Type: Peptide”
cagrilintide · Identity and approval
Identity
Cagrilintide is described as a long-acting analog in the amylin pathway.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The amylin pathway has re-emerged through long-acting analogs (cagrilintide, eloralintide) and unimolecular co-agonists (amycretin)”
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. · Abstract
Identity
Cagrilintide is a dual amylin and calcitonin-receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“dual amylin and calcitonin-receptor agonists (eg, cagrilintide)”
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? · Abstract
Identity
CagriSema combines semaglutide and cagrilintide (2.4 mg/2.4 mg).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg)”
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. · BACKGROUND
Identity
CagriSema combines semaglutide and cagrilintide in a fixed ratio.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide”
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. · Abstract
Identity
Coadministration of cagrilintide and semaglutide is called CagriSema.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“coadministration of cagrilintide and semaglutide (called CagriSema)”
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. · BACKGROUND
Identity
Cagrilintide is a long-acting amylin-based agent.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Recent advances in peptide engineering, lipidation, and reversible albumin binding have enabled the development of long-acting amylin-based agents, including cagrilintide, eloralintide, petrelintide and NN1213.”
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. · Abstract
Identity
Cagrilintide is a long-acting amylin agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide is a long-acting amylin agonist”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · BACKGROUND AND OBJECTIVES
Identity
Cagrilintide is a long-acting amylin analogue being studied for weight management.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide is a long-acting amylin analogue under investigation for weight management.”
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. · BACKGROUND
Identity
Cagrilintide is listed as a peptide-based amylin receptor agonist (AMYRA).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists (AMYRAs), including pramlintide and cagrilintide,”
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies. · Abstract
Identity
Cagrilintide is an amylin analog.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance.”
The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies · Abstract
Identity
Cagrilintide is a once-weekly amylin receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide, a once-weekly amylin receptor agonist”
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. · BACKGROUND
Identity
Cagrilintide is an amylin receptor agonist.
2 cited sources · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Given that amylin signalling is a key therapeutic target for next-generation weight-loss drugs, amylin receptor agonists such as pramlintide, cagrilintide and KBP-066 also warrant consideration as to metabolism and detection strategies in sports drug testing programs.”
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. · Abstract
- supports · Source-backed record
“Amylin receptor agonists such as cagrilintide represent emerging obesity therapies.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Identity
CagriSema combines cagrilintide (an amylin receptor agonist) with semaglutide (a GLP-1 receptor agonist) for once-weekly dosing.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · BACKGROUND
Identity
Cagrilintide is an amylin analog.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.”
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. · Abstract
Identity
Cagrilintide is a long-acting amylin analogue (as part of CagriSema).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.”
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. · Abstract
Identity
Cagrilintide (Cagri) is a dual agonist of amylin receptors (AMYRs) and the calcitonin receptor (CTR).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide (Cagri), functioning as a dual amylin receptor (AMYRs) and calcitonin receptor (CTR) agonist (DACRA)”
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. · Abstract
Identity
Cagrilintide is a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule type: Protein”
CAGRILINTIDE · Molecule identity
Identity
CagriSema combines cagrilintide and semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CagriSema (a combination of cagrilintide and semaglutide, -17.32%, -19.32% to -15.32%).”
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. · RESULTS
Identity
Cagrilintide is a long-acting amylin analogue.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · BACKGROUND
How does it work?
Target, response, and disposition.
Mechanism
Acute cagrilintide changes gene expression in area postrema Calcr/Ramp3 neurons.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“While acute cagrilintide treatment alters gene expression in area postrema Calcr/Ramp3 neurons, chemogenetic activation in rats fails to affect long-term food intake and body weight.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Mechanism
CHEMBL4802169 activated the human AMY1 amylin receptor complex in a HeLa-cell cAMP assay (EC50 0.01862 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Amylin receptor AMY1, CALCR/RAMP1 (CHEMBL2111189) Assay: Agonist activity at human AMY1R complex of CTR/RAMP1 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 0.01862 nM pChEMBL value: 10.73 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914942
Mechanism
For CHEMBL4802169 at the human AM1 receptor complex in a HeLa-cell cAMP assay, the activity result was not reported.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Adrenomedullin receptor AM1; CALCRL/RAMP2 (CHEMBL2109232) Assay: Agonist activity at human AM1R complex of CRLR/RAMP2 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: Activity not reported Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914958
Mechanism
Cagrilintide was tested for effects on mitochondria in C2C12 muscle cells under healthy and palmitic-acid conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This study aimed to investigate the effects of semaglutide (GLP-1RA), tirzepatide (dual GLP-1/GIP agonist) and cagrilintide (amylin analogue) on mitochondrial function in C2C12 skeletal muscle myotubes under both healthy and lipotoxic (palmitic acid-treated) conditions.”
Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. · BACKGROUND
Mechanism
CHEMBL4802169 activated the human CGRP receptor complex in a HeLa-cell cAMP assay (EC50 562.34 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 (CHEMBL2107838) Assay: Agonist activity at human CGRPR complex of CRLR/RAMP1 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 562.34 nM pChEMBL value: 6.25 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914954
Mechanism
Calcr/Prlh neurons are identified as mediators of amylin receptor agonist action.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Our study provides a cross-species spatially resolved atlas of DVC cell populations and defines Calcr/Prlh neurons as mediators of amylin receptor agonist action.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Mechanism
QT assay sensitivity was shown using moxifloxacin as the positive control.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“QT assay sensitivity was demonstrated with moxifloxacin as a positive control.”
Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participants · Abstract
Mechanism
CHEMBL4802169 activated the human AMY3 amylin receptor complex in a HeLa-cell cAMP assay (EC50 0.04677 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Amylin receptor AMY3; CALCR/RAMP3 (CHEMBL2111190) Assay: Agonist activity at human AMY3R complex of CTR/RAMP3 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 0.04677 nM pChEMBL value: 10.33 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914950
Mechanism
Cagrilintide binds AMY1R and CTR in similar “bypass” modes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagri adopts similar "bypass" binding modes in both receptors”
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. · Abstract
Mechanism
CHEMBL4802169 activated the human calcitonin receptor in a HeLa-cell cAMP assay (EC50 0.02291 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Calcitonin receptor (CHEMBL1832) Assay: Agonist activity at human CTR transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 0.02291 nM pChEMBL value: 10.64 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914938
Mechanism
The study used cryo-EM structures of cagrilintide bound to AMY1R-Gs and CTR-Gs complexes to explain a non-selective activation mechanism.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This study elucidates the non-selective activation mechanism by determining cryo-EM structures of Cagri bound to AMY1R-Gsand CTR-Gscomplexes.”
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. · Abstract
Mechanism
The paper claims to be the first systematic study of cagrilintide metabolism (along with pramlintide and KBP-066).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This study provides the first systematic metabolic characterization of pramlintide, cagrilintide and KBP-066.”
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. · Abstract
Mechanism
Two studies tested how kidney or liver impairment affects cagrilintide pharmacokinetics, safety, and tolerability after a single dose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Two studies were conducted to assess the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following single doses of cagrilintide.”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · BACKGROUND AND OBJECTIVES
Mechanism
P37 at cagrilintide’s C-terminus interacts with the receptor ECD.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“C-terminal P37Cagriinteraction with the receptor ECD”
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. · Abstract
Mechanism
CHEMBL4802169 activated the human AM2 receptor complex in a HeLa-cell cAMP assay (EC50 758.58 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Adrenomedullin receptor, AM2; CALCRL/RAMP3 (CHEMBL2111191) Assay: Agonist activity at human AM2R complex of CRLR/RAMP3 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 758.58 nM pChEMBL value: 6.12 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914962
Mechanism
In rats, long-term cagrilintide increases Prlh expression in nucleus of the solitary tract Calcr/Prlh cells.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In contrast, long-term cagrilintide treatment in rats upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh cells that are conserved across rodents, macaques and humans.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Mechanism
Researchers built a transcriptomics atlas of over 530,000 cells (80 neuron populations) across rat, mouse, and macaque caudal brainstem, and mapped them in the rat DVC.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC).”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Mechanism
These nucleus of the solitary tract Calcr/Prlh cells are conserved across rodents, macaques, and humans.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In contrast, long-term cagrilintide treatment in rats upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh cells that are conserved across rodents, macaques and humans.”
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. · Abstract
Mechanism
CHEMBL4802169 activated the human AMY2 amylin receptor complex in a HeLa-cell cAMP assay (EC50 0.04266 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule: CHEMBL4802169 Target: Amylin receptor AMY2; CALCR/RAMP2 (CHEMBL2364173) Assay: Agonist activity at human AMY2R complex of CTR/RAMP2 transduced in human HeLa cells by cAMP assay Assay format: cell-based format Standard result: EC50 = 0.04266 nM pChEMBL value: 10.37 Document: CHEMBL5523739”
ChEMBL activities for CHEMBL4802169 · Activity 25914946
Mechanism
The researchers analyzed rat samples taken after dosing to look for cagrilintide and its metabolites.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For comparison, authentic post-administration rat samples were analysed for cagrilintide and respective biotransformation products.”
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. · Abstract
Pharmacokinetics
Primary endpoint: cagrilintide AUC0-∞ from day 1 to day 36 (renal study) or day 39 (hepatic study).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary endpoint was area under the cagrilintide plasma concentration curve from time zero extrapolated to infinity (AUC0-∞) from baseline (day 1) to day 36 (renal impairment study) or day 39 (hepatic impairment study).”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · METHODS
Pharmacokinetics
Compared with normal liver function, AUC0-∞ ratios were 0.99 (0.89-1.11) mild, 1.01 (0.91-1.12) moderate, and 1.11 (0.96-1.30) severe impairment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with normal hepatic function, the estimated ratio of the mean AUC0-∞was 0.99 (0.89-1.11) in mild impairment, 1.01 (0.91-1.12) in moderate impairment and 1.11 (0.96-1.30) in severe impairment.”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · RESULTS
Pharmacokinetics
The main PK measure was AUC0-∞ from day 1 to day 36 (renal study) or to day 39 (hepatic study).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary endpoint was area under the cagrilintide plasma concentration curve from time zero extrapolated to infinity (AUC0-∞) from baseline (day 1) to day 36 (renal impairment study) or day 39 (hepatic impairment study).”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · METHODS
Pharmacokinetics
Metabolites predicted from in vitro work were also found in rat plasma after administration, supporting in vivo relevance for cagrilintide metabolites.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide metabolites predicted from in vitro experiments were observed in authentic post administration rat plasma samples, confirming in vivo relevance.”
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. · Abstract
Pharmacokinetics
Compared with normal kidney function, AUC0-∞ ratios were 1.23 (0.91-1.66) mild, 1.18 (0.87-1.59) moderate, and 1.21 (0.87-1.68) severe impairment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with normal renal function, the estimated ratio of the mean AUC0-∞was 1.23 (90% confidence interval [CI], 0.91-1.66) in mild impairment, 1.18 (0.87-1.59) in moderate impairment and 1.21 (0.87-1.68) in severe impairment.”
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. · RESULTS
What has been studied?
What the evidence says.
Comparative evidence
For assay sensitivity, placebo-arm participants received a single 400 mg oral moxifloxacin dose (positive control) and moxifloxacin placebo in a nested crossover.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To establish QT assay sensitivity, participants in the placebo arms received a single 400‐mg oral moxifloxacin dose as a positive control and moxifloxacin placebo in a nested cross‐over fashion.”
Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participants · Abstract
Comparative evidence
At week 40, cagrilintide-semaglutide reduced bodyweight more than placebo: treatment difference -12·4 percentage points (2·4 mg each) and -10·4 percentage points (1·0 mg each).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide-semaglutide was superior to placebo with respect to estimated mean relative change in bodyweight from baseline to week 40 for cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001) and cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001).”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
From baseline to week 40, bodyweight decreased more with cagrilintide-semaglutide (2·4 mg each) than placebo by -12·4 percentage points (95% CI -14·7 to -10·1; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide-semaglutide was superior to placebo with respect to estimated mean relative change in bodyweight from baseline to week 40 for cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001) and cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001).”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
Compared with placebo at 40 weeks, HbA1c was lower by -1·7 percentage points with cagrilintide-semaglutide (2·4 mg each) and by -1·3 percentage points with (1·0 mg each).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This corresponded to an estimated treatment difference of -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001) for cagrilintide-semaglutide (2·4 mg each) versus placebo and -1·3 percentage points (-1·8 to -0·9; p<0·0001) for cagrilintide-semaglutide (1·0 mg each) versus placebo.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
A systematic review and meta-analysis compared cagrilintide alone with semaglutide in people with obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.”
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression · Abstract
Comparative evidence
In lean rats, eloralintide caused less conditioned taste avoidance than cagrilintide (p < 0.05).
1 cited source · 1 linked study ID
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05).”
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. · RESULTS
Comparative evidence
In people with obesity, cagrilintide alone led to weight loss comparable to semaglutide in the included RCTs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide monotherapy weight loss was comparable to semaglutide.”
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. · RESULTS
Comparative evidence
At week 40, CagriSema 1·0 mg each was -11·8% bodyweight vs -1·4% with placebo; the difference was -10·4 percentage points.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“cagrilintide-semaglutide (1·0 mg each; -11·8% [1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -10·4 percentage points [-12·9 to -8·0]; p<0·0001)”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
In early-stage type 2 diabetes, cagrilintide-semaglutide (2·4 mg each or 1·0 mg each) was reported as superior to placebo for reducing HbA1c.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In a population of people with early-stage type 2 diabetes inadequately controlled with diet and exercise, cagrilintide-semaglutide (2·4 mg each and 1·0 mg each) was superior to placebo in reducing HbA1c.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · INTERPRETATION
Comparative evidence
At 40 weeks, HbA1c was lower with cagrilintide-semaglutide (2·4 mg each) than placebo by -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This corresponded to an estimated treatment difference of -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001) for cagrilintide-semaglutide (2·4 mg each) versus placebo and -1·3 percentage points (-1·8 to -0·9; p<0·0001) for cagrilintide-semaglutide (1·0 mg each) versus placebo.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
Compared with placebo at 40 weeks, CagriSema lowered HbA1c more by -1·7 (2·4 mg each) and -1·3 (1·0 mg each) percentage points.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This corresponded to an estimated treatment difference of -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001) for cagrilintide-semaglutide (2·4 mg each) versus placebo and -1·3 percentage points (-1·8 to -0·9; p<0·0001) for cagrilintide-semaglutide (1·0 mg each) versus placebo.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
At week 40, CagriSema 2·4 mg each was -13·8% bodyweight vs -1·4% with placebo; the difference was -12·4 percentage points.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“cagrilintide-semaglutide (2·4 mg each; -13·8% [SE 1·0]) versus placebo (-1·4% [0·7]; estimated treatment difference -12·4 percentage points [95% CI -14·7 to -10·1]; p<0·0001)”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Comparative evidence
Under the trial product estimand, cagrilintide 4·5 mg reduced weight more than liraglutide 3·0 mg (10·8% vs 9·0%; p=0·03).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Weight reductions were also greater with cagrilintide 4·5 mg versus liraglutide 3·0 mg (10·8% [11·5 kg] vs 9·0% [9·6 kg]; estimated treatment difference 1·8%, p=0·03).”
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. · FINDINGS
Study findings
CagriSema significantly reduced waist circumference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CagriSema produced a significant reduction in waist circumference and HbA1c”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · RESULTS
Study findings
The primary endpoint was percent (relative) change in bodyweight from baseline to week 68.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary endpoint was relative change in bodyweight from baseline to week 68.”
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. · METHODS
Study findings
After 40 weeks, HbA1c changed by -1·8 percentage points with cagrilintide-semaglutide (2·4 mg each), -1·5 percentage points with (1·0 mg each), and -0·1 percentage points with placebo (efficacy estimand).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Using the efficacy estimand, the estimated mean change in HbA1cafter 40 weeks was -1·8 percentage points (SE 0·1) with cagrilintide-semaglutide (2·4 mg each), -1·5 percentage points (0·1) with cagrilintide-semaglutide (1·0 mg each), and -0·1 percentage points (0·2) with placebo.”
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · FINDINGS
Study findings
Compared with placebo, CagriSema (cagrilintide + semaglutide) was linked to -17.32% weight loss (95% CI -19.32% to -15.32%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with placebo, weight loss was greatest with retatrutide (-22.10%, 95% confidence interval -25.60% to -18.60%), followed by tirzepatide (-19.28%, -20.39% to -18.16%), and CagriSema (a combination of cagrilintide and semaglutide, -17.32%, -19.32% to -15.32%).”
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. · RESULTS
Study findings
CagriSema caused more weight loss than cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02; p < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CagriSema produced significantly greater weight loss than semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001), cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02, p < 0.00001), and placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001).”
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. · Abstract
Study findings
At week 68, HbA1c decreased more with cagrilintide-semaglutide (2·4 mg each) than with semaglutide 2·4 mg (difference -0·16 percentage points; p=0·0035).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For the primary endpoint using the efficacy estimand, mean HbA1cchange was significantly greater with cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg (-1·91 percentage points [SE 0·04] vs -1·75 percentage points [0·04]; estimated treatment difference -0·16 percentage points [95% CI -0·27 to -0·05]; p=0·0035).”
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. · FINDINGS
Study findings
CagriSema significantly reduced HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CagriSema produced a significant reduction in waist circumference and HbA1c”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · RESULTS
Study findings
For placebo-adjusted QTcF change from baseline, the two-sided 90% CI upper limits were below 10 ms at all time points.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“the upper limits of the two‐sided 90% CIs of the placebo‐adjusted QTcF changes from baseline were below 10 ms at all time points.”
Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participants · Abstract
Study findings
Across pooled trials, CagriSema reduced percent body weight versus placebo (mean difference - 5.98%, 95% CI - 10.64 to - 1.32).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide significantly reduced percent body weight versus placebo (mean difference - 6.08%, 95% CI - 8.02 to - 4.14)”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · RESULTS
- supports · Source-backed record
“as did CagriSema (- 5.98%, 95% CI - 10.64 to - 1.32).”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · RESULTS
Study findings
In adults with type 2 diabetes and BMI 27 or higher, once-weekly cagrilintide-semaglutide (2.4 mg each) for 68 weeks reduced body weight more than placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001).”
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. · RESULTS
Study findings
In REDEFINE 1, antihypertensive secondary/post hoc analyses focused on CagriSema versus placebo (not the cagrilintide arm).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Secondary and post hoc analyses evaluated the antihypertensive effect from REDEFINE 1, focusing on CagriSema and placebo groups”
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. · METHODS
Study findings
In REDEFINE 5, cagrilintide-semaglutide lowered bodyweight more than semaglutide by week 68.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The estimated mean change in bodyweight from baseline to week 68 was -18·4% (SE 0·7) in the cagrilintide-semaglutide group versus -11·9% (0·7) in the semaglutide group (estimated treatment difference [ETD] -6·5 percentage points [95% CI -8·4 to -4·6]; p<0·0001).”
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. · FINDINGS
Study findings
By week 26, cagrilintide 0·3-4·5 mg reduced bodyweight more than placebo (6·0%-10·8% vs 3·0%; p<0·001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“According to the trial product estimand, mean percentage weight reductions from baseline were greater with all doses of cagrilintide (0·3-4·5 mg, 6·0%-10·8% [6·4-11·5 kg]) versus placebo (3·0% [3·3 kg]; estimated treatment difference range 3·0%-7·8%; p<0·001).”
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. · FINDINGS
Study findings
REDEFINE 1 randomized 302 participants to cagrilintide.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Overall, 3417 participants underwent randomization; CagriSema: n=2108, semaglutide: n=302, cagrilintide: n=302, and placebo: n=705.”
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. · RESULTS
Study findings
Cagrilintide-semaglutide (2·4 mg each) reduced HbA1c more than semaglutide 2·4 mg in people with type 2 diabetes on metformin (with or without an SGLT2 inhibitor).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Cagrilintide-semaglutide (2·4 mg each) was superior to semaglutide 2·4 mg in reducing HbA1cin participants with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor.”
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. · INTERPRETATION
Study findings
The analysis assessed weight-related outcomes, HDL-C, and several safety outcomes, including gastrointestinal adverse events and treatment discontinuation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Outcomes included changes in percent body weight, absolute weight, waist circumference, BMI, patients achieving ≥ 5% to ≥ 20% weight loss, HDL-C and safety outcomes (AEs, serious AEs, gastrointestinal AEs and treatment discontinuation).”
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. · METHODS
Study findings
Compared with lifestyle modification alone, cagrilintide-semaglutide (CagriSema) was linked to -14.8% weight loss at one year (95% CI -16.9% to -12.7%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%).”
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. · RESULTS
Study findings
Four randomized trials with 5425 participants were included.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Four RCTs encompassing 5425 participants were included.”
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. · RESULTS
Study findings
Both cagrilintide and CagriSema reduced absolute body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Both interventions significantly reduced absolute body weight.”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · RESULTS
Study findings
The main outcome assessed was percent change in body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary outcome was percent change in body weight.”
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. · METHODS
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
18 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (18)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide’s binding mode is said to differ from other DACRAs that mainly extend half-life via N-terminal lipid modification.
Research context only—not evidence of a treatment effect.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
which is distinct from other existing DACRAs that primarily achieve extended half-life through N-terminal lipid modification.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review evaluated cagrilintide alone and cagrilintide with semaglutide (CagriSema) for weight management.
Research context only—not evidence of a treatment effect.
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Giving GLP-1R and CTR/AMYR agonists together into the LDTg suppressed food intake more than either one alone.
Research context only—not evidence of a treatment effect.
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
co-administration of GLP-1R and CTR/AMYR agonists into the LDTg resulted in a greater suppression of food intake
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide non-selectively activates Gs signaling via CTR and AMY1R.
Research context only—not evidence of a treatment effect.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
Both structural and functional analyses revealed Cagri's non-selective activation of Gssignaling pathways through CTR and AMY1R.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Amylin increases satiety by lowering appetite, regulating glucose, and slowing stomach emptying.
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
Amylin promotes the satiating effect through multiple pathways (decreases appetite, regulates glucose levels, slows gastric emptying).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Secondary outcomes included absolute weight change, waist circumference, blood pressure, HbA1c, and safety outcomes.
Research context only—not evidence of a treatment effect.
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Secondary outcomes included absolute weight change, waist circumference, blood pressure, glycated hemoglobin (HbA1c), and safety outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Co-activating GLP-1R and CTR/AMYR in the LDTg suppressed both homeostatic and motivation-related feeding more than monotherapy.
Research context only—not evidence of a treatment effect.
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Overall, intra-LDTg co-agonism of GLP-1Rs and CTR/AMYRs produced a greater suppressive effect on homeostatic and motivational aspects of feeding behavior than monotherapy alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was body-weight change; other outcomes included glycemia, lipids, and adverse events.
Research context only—not evidence of a treatment effect.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
NNC0174-0833 is listed as a synonym.
Research context only—not evidence of a treatment effect.
- CAGRILINTIDE
Cagrilintide; Cagrilintide component of cagrisema; NNC0174-0833
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema is a fixed-dose combination of cagrilintide and semaglutide.
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
its fixed-dose combination with semaglutide (CagriSema)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide has ChEMBL ID CHEMBL4802169.
Research context only—not evidence of a treatment effect.
- CAGRILINTIDE
ChEMBL ID: CHEMBL4802169
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The preferred name is CAGRILINTIDE.
Research context only—not evidence of a treatment effect.
- CAGRILINTIDE
Preferred name: CAGRILINTIDE
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide is also listed as a synonym.
Research context only—not evidence of a treatment effect.
- CAGRILINTIDE
Cagrilintide; Cagrilintide component of cagrisema; NNC0174-0833
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide is combined with semaglutide as a fixed-dose combination called CagriSema.
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
its fixed-dose combination with semaglutide (CagriSema)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema is cagrilintide + semaglutide.
Research context only—not evidence of a treatment effect.
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Before this study, cagrilintide’s structural activation mechanism was unclear.
Research context only—not evidence of a treatment effect.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
although its structural activation mechanism remains unclear.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cagrilintide has an E14–R17 intramolecular salt bridge that enhances helical stability.
Research context only—not evidence of a treatment effect.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
an E14-R17 intramolecular salt bridge enhancing helical stability
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Amylin produces satiety through both homeostatic and hedonic brain regions.
Research context only—not evidence of a treatment effect.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain.
Research status + gaps
What still needs better answers?
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
- Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- ChEMBL activities for CHEMBL4802169 ↗
chembl-activities · published August 25, 2026 · retrieved August 25, 2026
- CAGRILINTIDE ↗
chembl-molecule · published August 25, 2026 · retrieved August 25, 2026
- Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participants ↗
doi · published September 16, 2024 · retrieved September 9, 2026
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression ↗
doi · published March 16, 2026 · retrieved September 8, 2026
- The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies ↗
doi · published January 1, 2025 · retrieved September 4, 2026
- IUPHAR ligand commentary ↗
iuphar-comments · published August 25, 2026 · retrieved August 25, 2026
- cagrilintide ↗
iuphar-ligand · published August 25, 2026 · retrieved August 25, 2026
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. ↗
pubmed · published December 11, 2021 · retrieved September 8, 2026
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. ↗
pubmed · published September 9, 2026 · retrieved September 9, 2026
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. ↗
pubmed · published January 1, 2024 · retrieved September 9, 2026
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. ↗
pubmed · published August 14, 2025 · retrieved September 4, 2026
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. ↗
pubmed · published January 1, 2026 · retrieved September 8, 2026
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. ↗
pubmed · published March 11, 2026 · retrieved August 25, 2026
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. ↗
pubmed · published December 1, 2025 · retrieved September 10, 2026
- Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? ↗
pubmed · published December 20, 2026 · retrieved August 25, 2026
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. ↗
pubmed · published February 1, 2026 · retrieved September 2, 2026
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies. ↗
pubmed · published March 1, 2026 · retrieved September 2, 2026
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. ↗
pubmed · published June 15, 2026 · retrieved August 17, 2026
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. ↗
pubmed · published June 1, 2026 · retrieved September 2, 2026
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. ↗
pubmed · published April 1, 2026 · retrieved September 2, 2026
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. ↗
pubmed · published June 1, 2026 · retrieved August 25, 2026
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. ↗
pubmed · published June 1, 2026 · retrieved September 2, 2026
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. ↗
pubmed · published June 1, 2026 · retrieved September 2, 2026
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. ↗
pubmed · published July 1, 2026 · retrieved August 26, 2026
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. ↗
pubmed · published July 1, 2026 · retrieved September 2, 2026
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. ↗
pubmed · published August 1, 2026 · retrieved August 21, 2026
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. ↗
pubmed · published August 1, 2026 · retrieved August 21, 2026
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. ↗
pubmed · published June 1, 2026 · retrieved September 2, 2026
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. ↗
pubmed · published July 8, 2026 · retrieved August 24, 2026
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. ↗
pubmed · published August 1, 2026 · retrieved August 19, 2026
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. ↗
pubmed · published August 12, 2026 · retrieved August 25, 2026
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. ↗
pubmed · published November 1, 2026 · retrieved September 11, 2026
- Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. ↗
pubmed · published August 17, 2026 · retrieved August 18, 2026
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. ↗
pubmed · published January 1, 2026 · retrieved September 5, 2026
Publication history and provenance
Version 20 · Automated assessment · September 11, 2026
ec67dfee1cf2b446547a8f1ff0d2b52d879011492f1df94b8cd2c1e55ab1ddb6